Table 1 Baseline characteristics of the patients in the two treatment groups
Characteristics | Sorafenib (n = 56) | Sorafenib + TACE (n = 48) | Total (n = 104) | P |
|---|---|---|---|---|
Gender | ||||
 Male, n (%) | 48 (85.71%) | 46 (95.83%) | 94 (90.38%) | 0.103 |
 Female, n (%) | 8 (14.29%) | 2(4.17%) | 10 (9.62%) | |
Age (years) | 50.23 ± 11.88 | 47.6 ± 12.73 | 49.02 ± 12.29 | 0.279 |
Antiviral therapy | ||||
 Yes, n (%) | 25 (44.64%) | 27 (56.25%) | 52 (50%) | 0.238 |
 No, n (%) | 31 (55.36%) | 21 (43.75%) | 52 (50%) | |
Positive for HBsAg | ||||
 Yes, n (%) | 48 (85.71%) | 45 (93.75%) | 93 (89.42%) | 0.184 |
 No, n (%) | 8 (14.29%) | 3 (6.25%) | 11 (10.58%) | |
Liver cirrhosis | ||||
 Yes, n (%) | 45 (80.36%) | 32 (66.67%) | 77 (74.04%) | 0.112 |
 No, n (%) | 11 (19.64%) | 16 (33.33%) | 27 (25.96%) | |
PVH | ||||
 Yes, n (%) | 34 (60.71%) | 27 (56.25%) | 61 (58.65%) | 0.645 |
 No, n (%) | 22 (39.29%) | 21 (43.75%) | 43 (41.35%) | |
Ascites | ||||
 Yes, n (%) | 14 (25%) | 8 (16.67%) | 22 (21.15%) | 0.3 |
 No, n (%) | 42 (75%) | 40 (83.33%) | 82 (78.85%) | |
Splenomegaly | ||||
 Yes, n (%) | 30 (53.57%) | 24 (50%) | 54 (51.92%) | 0.716 |
 No, n (%) | 26 (46.43%) | 24 (50%) | 50 (48.08%) | |
Esophageal varix | ||||
 None, n (%) | 46 (82.14%) | 44 (91.67%) | 90 (86.54%) | 0.220 |
 Mild, n (%) | 7 (12.5%) | 2(4.17%) | 9 (8.65%) | |
 Moderate, n (%) | 1 (1.79%) | 2 (4.17%) | 3 (2.88%) | |
 Severe, n (%) | 2 (3.57%) | 0 | 2 (1.92%) | |
Diabetes | ||||
 Yes, n (%) | 5 (8.93%) | 1 (2.08%) | 6 (5.77%) | 0.214 |
 No, n (%) | 51 (91.07%) | 47(97.92%) | 98 (94.23%) | |
Tumor number | 2 (1,4) | 2 (1,4) | 2 (1,4) | 0.169 |
Tumor diameter (cm) | 9.1 (1,19.5) | 7.65 (1,19) | 8.65 (1,19.5) | 0.172 |
Vascular invasion | ||||
 Yes, n (%) | 37 (66.07%) | 26 (54.17%) | 41 (39.42%) | 0.216 |
 No, n (%) | 19 (33.93%) | 22 (45.83%) | 63 (60.58%) | |
Metastasis, n (%) | ||||
 Yes, n (%) | 17 (30.36%) | 21 (43.75%) | 38 (36.54%) | 0.157 |
 No, n (%) | 39 (69.64%) | 27 (56.25%) | 66 (63.46%) | |
BCLC stage B/C | ||||
 B, n (%) | 10 (17.86%) | 16 (33.33%) | 26 (25%) | 0.069 |
 C, n (%) | 46 (82.14%) | 32 (66.67%) | 78 (75%) | |
Child-Pugh stage A/B | ||||
 A, n (%) | 45 (80.36%) | 46 (95.83%) | 91 (87.50%) | 0.017 |
 B, n (%) | 11 (19.64%) | 2 (4.17%) | 13 (12.50%) | |
TBil (μmol/L) | 12.45 (2.9,49.5) | 12.5 (5,34.9) | 12.45 (2.9,49.5) | 0.500 |
ALT (IU/L) | 41.5 (4171) | 42.5 (13,199) | 42 (4199) | 0.469 |
ALB (g/L) | 39.23 ± 4.94 | 41.44 ± 5.14 | 40.25 ± 5.13 | 0.028 |
PT (s) | 13.05 (10.9,53) | 12.7 (10.4,16.4) | 12.85 (10.4,53) | 0.090 |
AFP (ng/mL) | 400 (0.78, 12,100) | 172.5 (1.4, 4000) | 350 (0.78, 12,100) | 0.203 |
  < 400 ng/mL, n (%) | 23 (48.94%) | 33 (58.93%) | 56 (54.37%) |  |
  ≥ 400 ng/mL, n (%) | 24 (51.06%) | 23 (41.07%) | 47 (45.63%) |  |
PVTT, n (%) | ||||
 I | 11 (19.64%) | 5 (10.42%) | 16 (15.38%) | 0.254 |
 II | 10 (17.86%) | 13 (22.12%) | 23 (22.12%) | |
 III | 8 (14.29%) | 6 (12.5%) | 14 (13.46%) | |
 IV | 3 (5.36%) | 0 | 3 (2.88%) | |